Corticosteroid
Desonide
The FDA lists this product in 20 strengths and forms.
Indications
Desonide Gel, 0.05% is indicated for the treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. Patients should be instructed to use Desonide Gel, 0.05% for the minimum amount of time as necessary to achieve the desired results because of the potential for Desonide Gel, 0.05% to suppress the hypothalamicpituitary-adrenal (HPA) axis [see Warnings and Precautions ( 5.1 )]. Treatment should not exceed 4 consecutive weeks [see Dosage and Administration ( 2 )].
Desonide Gel, 0.05% is a corticosteroid indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. ( 1 )
Contraindications
Desonide Gel, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. History of hypersensitivity to any of the components of the preparation.
Warnings and precautions
- Topical corticosteroids can produce reversible hypothalamic pituitary adrenal (HPA) axis suppression, Cushing’s syndrome and unmask latent diabetes. ( 5.1 )
- Systemic absorption may require evaluation for HPA axis suppression. ( 5.1 )
- Modify use should HPA axis suppression develop ( 5.1 )
- Potent corticosteroids, use on large areas, prolonged use or occlusive use may increase systemic absorption ( 5.1 )
- Local adverse reactions may include atrophy, striae, irritation, acneiform eruptions, hypopigmentation, and allergic contact dermatitis and may be more likely with occlusive use or more potent corticosteroids. ( 5.2 , 5.4 , 6 )
- Children may be more susceptible to systemic toxicity when treated with topical corticosteroids. ( 5.1 , 8.4 )
5.1Effects on Endocrine System
Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for clinical glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of the topical corticosteroid. The effect of Desonide Gel, 0.05% on HPA axis function was investigated in pediatric subjects, 6 months to 6 years old, with atopic dermatitis covering at least 35% of their body, who were treated with Desonide Gel, 0.05% twice daily for 4 weeks.



